RespireRx Pharmaceuticals Inc. (RSPI) financial statements (2023 and earlier)

Company profile

Business Address 126 VALLEY ROAD
GLEN ROCK, NJ 07452
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 11733859253
Cash and cash equivalents 11733859253
Prepaid expense 322939435529
Deferred costs 53    3
Other undisclosed current assets   494949 
Total current assets: 854512117719686
Noncurrent Assets
Property, plant and equipment    (21)512
Prepaid expense   3183348
Other undisclosed noncurrent assets    21  
Total noncurrent assets:   3183860
TOTAL ASSETS: 8545124195234146
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 4,9243,7723,3032,9222,4951,434
Employee-related liabilities 1,5412,0841,3044791,945710
Interest and dividends payable      61
Other undisclosed accounts payable and accrued liabilities 3,3831,6881,9992,443550663
Debt 419556249383343302
Due to related parties 865766744584594562
Other undisclosed current liabilities 1,9402,3961,5616612,296710
Total current liabilities: 8,1487,4905,8574,5505,7273,008
Noncurrent Liabilities
Total liabilities: 8,1487,4905,8574,5505,7273,008
Temporary equity, carrying amount     185 
Stockholders' equity
Stockholders' equity attributable to parent, including: (8,063)(7,445)(5,733)(4,355)(5,493)(2,862)
Preferred stock 22222222  
Common stock 714432490
Additional paid in capital 162,654159,038158,635157,422151,994144,648
Accumulated deficit (170,810)(166,509)(164,394)(161,802)(157,511)(148,280)
Other undisclosed stockholders' equity attributable to parent     22280
Total stockholders' equity: (8,063)(7,445)(5,733)(4,355)(5,493)(2,862)
Other undisclosed liabilities and equity     (185) 
TOTAL LIABILITIES AND EQUITY: 8545124195234146

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues
(Revenue, Net)
      87
Gross profit:      87
Operating expenses (3,315)(1,737)(2,177)(4,247)(8,472)(5,327)
Operating loss: (3,315)(1,737)(2,177)(4,247)(8,472)(5,240)
Nonoperating income (expense)
(Foreign Currency Transaction Gain (Loss), before Tax)
 (50)26(113)   
Interest and debt expense (936)(405)(136)(102)(586)(903)
Net loss: (4,301)(2,115)(2,425)(4,350)(9,058)(6,142)
Other undisclosed net income (loss) attributable to parent   (166)58(172)180
Net loss attributable to parent: (4,301)(2,115)(2,592)(4,291)(9,230)(5,962)
Preferred stock dividends and other adjustments (1,440)   (1)(7)
Net loss available to common stockholders, diluted: (5,741)(2,115)(2,592)(4,291)(9,231)(5,969)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss: (4,301)(2,115)(2,425)(4,350)(9,058)(6,142)
Comprehensive loss, net of tax, attributable to parent: (4,301)(2,115)(2,425)(4,350)(9,058)(6,142)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: